Tesamorelin

Tesamorelin: A GHRH analogue investigated in hormonal signalling and visceral fat biology.

What is it?

A GHRH analogue investigated in hormonal signalling and visceral fat biology.

How it is studied

It stimulates the endogenous growth-hormone pathway. Research evaluates both hormonal effects and defined clinical outcomes.

What the evidence says

Regulated tesamorelin medicine has a specific indication for excess abdominal fat in HIV-associated lipodystrophy. This is not general weight-loss or anti-aging approval.

What remains uncertain

The approved formulation and clinical supervision are part of its evidence. These research listings are not that medicine. GH/IGF-1 and glucose-related effects make broader extrapolation inappropriate.

Sources & scope

FDA EGRIFTA WR prescribing information (2025)

For in-vitro laboratory research only. Not for human or veterinary use.